Miami – 
December 3, 2021, Progressive Care Inc. (the “Company” or “Progressive Care”)
held a special meeting of its stockholders (the “Special Meeting”). The record
date for stockholders entitled to notice of, and to vote at, the Special
Meeting was November 3, 2021. At the close of business on that date, the
Company had 535,430,294 shares of common stock, par value $0.0001 (“Common
Stock”) outstanding and 51 shares of Series A Preferred Stock (“Preferred
Stock”) outstanding, and entitled to be voted at the Special Meeting. At the
Special Meeting, the following three proposals were submitted to the Company’s
stockholders:
1. To approve an amendment to
the Company’s Certificate of Incorporation to effect, on or before February 16,
2023, a reverse split of the Company’s issued and outstanding common stock at a
ratio of between 1-for-10 to 1-for-250 if and when and at such ratio as may be
determined by the Company’s Board of Directors (“Proposal 1”);
2. To approve an amendment to the
Company’s Certificate of Incorporation, if and only if Proposal No. 1 is both
approved and implemented, to change the number of authorized shares of the
Company’s common stock from 1 billion (1,000,000,000) to 100 million
(100,000,000) (“Proposal 2”); and
3. To approve the adjournment of
the Special Meeting, if necessary, to solicit additional proxies if there are
not sufficient votes in favor of the foregoing proposals. (“Proposal 3”).
The final voting results were as
follows:
Proposal 1
The Company’s stockholders
approved Proposal 1. 259,216,375 shares of Common Stock and 51 shares of
Preferred Stock voted in favor of approval of the resolution, 88,388,079 shares
of Common Stock and 0 shares of Preferred Stock voted against approval of the
resolution, and 5,318,354 shares of Common Stock and 0 shares of Preferred
Stock abstained from voting for the approval of the resolution.
Proposal 2
The Company’s stockholders
approved Proposal 2. 183,520,010 shares of Common Stock and 51 shares of
Preferred Stock voted in favor of approval of the resolution, 53,039,600 shares
of Common Stock and 0 shares of Preferred Stock have voted against approval of
the resolution, and 10,111,762 shares of Common Stock and 0 shares of Preferred
Stock have abstained from voting for the approval of the resolution.
Proposal 3
The Company’s stockholders
approved Proposal 3. 284,433,452 shares of Common Stock and 51 shares of
Preferred Stock have been voted in favor of approval of the resolution,
57,690,777 shares of Common Stock and 0 shares of Preferred Stock have voted
against approval of the resolution, and 10,789,181 shares of Common Stock and 0
shares of Preferred Stock have abstained from voting for the approval of the
resolution.
Mr. Alan Jay Weisberg, CEO, and
Chairman of the Board, said, “I would like to express my appreciation to our
shareholders for trusting the Company’s Board and voting to approve the
Company’s recommendations. This vote will allow the Company to continue moving
towards accomplishing its goals of becoming a fully reporting company under the
SEC’s Exchange Act rules and becoming listed on Nasdaq. I want to assure every
one of our shareholders that we plan to carry on with our mission of redefining
healthcare, improving our financial position, and driving shareholder value.”
For more information about
Progressive Care, please visit the company’s website. Connect and stay in touch
with us on social media:
Progressive Care Inc.
https://www.facebook.com/ProgressiveCareUS/
https://twitter.com/ProgressCareUS
PharmCoRx
https://www.facebook.com/pharmcorx/
ClearMetrX
https://www.facebook.com/clearmetrx/
About Progressive Care:
Progressive Care Inc. (OTCQB:
RXMD), through its subsidiaries, is a Florida health services organization and
provider of Third-Party Administration (TPA), data management, COVID-19 related
diagnostics and vaccinations, 340B contracted pharmacy services, prescription
pharmaceuticals, compounded medications, provider of tele-pharmacy services,
the sale of anti-retroviral medications, medication therapy management (MTM),
the supply of prescription medications to long-term care facilities, and health
practice risk management.
Cautionary Disclosure Regarding Forward-Looking Statements
Forward-Looking Statements contained herein that are not based upon current or
historical fact are forward-looking in nature and constitute forward-looking statements
within the meaning of Section 27A of the Securities Act of 1933 and Section 21E
of the Securities Exchange Act of 1934. Such forward-looking statements reflect
the Company’s expectations about its future operating results, performance, and
opportunities that involve substantial risks and uncertainties. When used
herein, the words “anticipate,” “believe,” “estimate,” “upcoming,” “plan,”
“target,” “intend” and “expect” and similar expressions, as they relate to
Progressive Care Inc., its subsidiaries, or its management, are intended to
identify such forward-looking statements. These forward-looking statements are
based on information currently available to the Company and are subject to a
number of risks, uncertainties, and other factors that could cause the
Company’s actual results, performance, prospects, and opportunities to differ
materially from those expressed in, or implied by, these forward-looking
statements.
Public Relations Contact:
Carlos Rangel
carlosr@pharmcorx.com